ReviewJournal of cardiovascular translational research2009
Gender aspects in cardiovascular pharmacology.
Review in Journal of cardiovascular translational research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of High Potent P2YJournal of the American Heart Association · 2020Pooled it
- Clinical Trial Technologies for Improving Equity and Inclusion in Cardiovascular Clinical Research.Cardiology and therapy · 2023Article
- Clinical and psychological characteristics of patients with ischemia and non-obstructive coronary arteries (INOCA) and obstructive coronary artery disease.American heart journal plus : cardiology research and practice · 2023Article
- The Impact of Sex and Gender in Medicine and Pharmacology.Handbook of experimental pharmacology · 2023Article
- Adverse Reaction of Acupuncture and Antihypertensive Drugs for Treatment of Essential hypertension: A Protocol for Bayesian Network Meta-Analysis.Computational intelligence and neuroscience · 2022Article
- Cardiac medication use in patients with suspected ischaemia without obstructive coronary arteries: sex differences and psychological distress.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2021Article
- Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.International journal of environmental research and public health · 2021Article
- Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs.European journal of clinical pharmacology · 2018Article
- Gender differences in chemical carcinogenesis in National Toxicology Program 2-year bioassays.Toxicologic pathology · 2012Article
- Article
- Breakout session: Gender and ethnic disparities in pain management.Clinical orthopaedics and related research · 2011Article
- Analysis of sex and gender-specific research reveals a common increase in publications and marked differences between disciplines.BMC medicine · 2010Article
- Gender difference in the response to valsartan/amlodipine single-pill combination in essential hypertension (China Status II): An observational study.Journal of the renin-angiotensin-aldosterone system : JRAASObservational
- Sex-Specific Characteristics of the Microcirculation.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influence of biological sex on pharmacokinetics and pharmacodynamics has been previously described for each step of the metabolic cascade of pharmaceuticals. Women and men display differences in distribution, metabolism, and excretion of drugs for several biologic reasons. Estrogens are relevant in these processes, but cannot be regarded as the only responsible mechanism. Sex differences in the incidence of adverse drug reactions and pharmacotoxicity have also been reported for several classes of drugs and specifically for several cardiovascular preparations. Given the high incidence of cardiovascular conditions and thus the broad use of these drugs in the general population, these reports have to be considered of relevance to public health. Nonetheless, increased knowledge has not translated into the development and implementation of gender-specific pharmacologic guidelines which appear as the only effective strategy to minimize the incidence of sex-specific side effects and adverse drug reactions. In the present review, we analyze the basic aspects of sex-specific pharmacodynamics and present several examples of gender dimorphism in cardiovascular drugs. We also suggest measures to analyze and possibly improve current therapeutic strategies.
Indexed as
Identifiers
20560015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.